Waxman S - Search Results

1

Arsenic trioxide in multiple myeloma: rationale and future directions.

Anderson KC, Boise LH, Louie R, Waxman S. Anderson KC, et al. Among authors: waxman s. Cancer J. 2002 Jan-Feb;8(1):12-25. doi: 10.1097/00130404-200201000-00003. Cancer J. 2002. PMID: 11895198 Review.

2

Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.

Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC. Hayashi T, et al. Among authors: waxman s. Mol Cancer Ther. 2002 Aug;1(10):851-60. Mol Cancer Ther. 2002. PMID: 12492118

3

Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.

Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD. Slack JL, et al. Among authors: waxman s. Oncologist. 2002;7 Suppl 1:1-13. doi: 10.1634/theoncologist.7-suppl_1-1. Oncologist. 2002. PMID: 11961204 Free article. Review.

4

Mechanisms of action of arsenic trioxide.

Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Miller WH Jr, et al. Among authors: waxman s. Cancer Res. 2002 Jul 15;62(14):3893-903. Cancer Res. 2002. PMID: 12124315 Review.

5

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.

Shackelford D, Kenific C, Blusztajn A, Waxman S, Ren R. Shackelford D, et al. Among authors: waxman s. Cancer Res. 2006 Dec 1;66(23):11360-9. doi: 10.1158/0008-5472.CAN-06-1774. Cancer Res. 2006. PMID: 17145882

6

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.

Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ. Niu C, et al. Among authors: waxman s. Blood. 1999 Nov 15;94(10):3315-24. Blood. 1999. PMID: 10552940 Free article. Clinical Trial.

7

Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.

Wang R, Xia L, Gabrilove J, Waxman S, Jing Y. Wang R, et al. Among authors: waxman s. Leukemia. 2013 Feb;27(2):315-24. doi: 10.1038/leu.2012.180. Epub 2012 Jul 3. Leukemia. 2013. PMID: 22751450 Free PMC article.

8

Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.

Wang R, Liu C, Xia L, Zhao G, Gabrilove J, Waxman S, Jing Y. Wang R, et al. Among authors: waxman s. Clin Cancer Res. 2012 Dec 15;18(24):6690-701. doi: 10.1158/1078-0432.CCR-12-0770. Epub 2012 Oct 18. Clin Cancer Res. 2012. PMID: 23082001 Free PMC article.

9

Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.

Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, Chen Z, Waxman S. Chen GQ, et al. Among authors: waxman s. Cancer Res. 2003 Apr 15;63(8):1853-9. Cancer Res. 2003. PMID: 12702573

10

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.

Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH Jr. Shao W, et al. Among authors: waxman s. J Natl Cancer Inst. 1998 Jan 21;90(2):124-33. doi: 10.1093/jnci/90.2.124. J Natl Cancer Inst. 1998. PMID: 9450572

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,353 results

Search Page